Graft prosthesis, materials and methods
A graft prostheses ( 11 ), materials and method for implanting, transplanting, replacing, or repairing a part of a patient. The graft prosthesis includes a purified, collagen-based matrix structure removed from a submucosa tissue source. The submucosa tissue source is purified by disinfection and removal steps to deactivate and remove contaminants, thereby making the purified structure biocompatible and suitable for grafting on and/or in a patient.
1. A tissue matrix composition in the form of a powder, comprising:
a tissue matrix material obtained from mammalian urinary tract tissue, the tissue matrix material in the form of a sterile powder and including submucosa and lamina propria from the urinary tract tissue, wherein the tissue matrix material retains one or more native growth factors from the urinary tract tissue including Fibroblast Growth Factor-2.
2. The tissue matrix composition of claim 1 , wherein the tissue matrix material is obtained from a porcine tissue source.
3. The tissue matrix composition of claim 1 in combination with water so as to form a fluidized composition.
4. The tissue matrix composition of claim 1 in combination with buffered saline so as to form a fluidized composition.
5. The tissue matrix composition of claim 1 in combination with an aqueous carrier so as to form an injectable fluid composition.
6. The tissue matrix composition of claim 1 in combination with an aqueous carrier so as to form a gel.
7. The tissue matrix composition of claim 1 in combination with an aqueous carrier so as to form a paste.
8. The tissue matrix composition of claim 1 , wherein the tissue matrix material is in the form of a dried powder.
9. The tissue matrix composition of claim 1 , wherein the tissue matrix material additionally retains at least one native bioactive agent selected from the group consisting of a proteoglycan, a glycoprotein, and a glycosaminoglycan.
10. The tissue matrix composition of claim 1 , wherein the tissue matrix material is remodelable.
11. The tissue matrix composition of claim 1 , wherein the one or more native growth factors includes Transforming Growth Factor-β.
12. The tissue matrix composition of claim 1 , wherein the tissue matrix material additionally retains a proteoglycan, a glycoprotein, and a glycosaminoglycan from the urinary tract tissue.
13. The tissue matrix composition of claim 1 , wherein the tissue matrix material is effective to promote regrowth of damaged tissue structures.
14. The tissue matrix composition of claim 13 , wherein the tissue matrix material has not been treated with a chemical crosslinking agent.
15. The tissue matrix composition of claim 1 , wherein the tissue matrix material has a bioburden level of less than 0.5 colony forming units per gram, a nucleic acid content level of less than 2 micrograms per milligram, a virus level of less than 5 plaque forming unit per gram, and a fungus level of less than 0.5 colony forming units per gram.
16. The tissue matrix composition of claim 1 , wherein the tissue matrix material has been sterilized through contact with an aqueous solution containing a peracid.
17. The tissue matrix composition of claim 16 , wherein the peracid is peracetic acid.
18. The tissue matrix composition of claim 1 , wherein the tissue matrix material has not been treated with a crosslinking agent.
19. The tissue matrix composition of claim 15 , wherein the tissue matrix material has not been treated with a chemical crosslinking agent.
20. A tissue matrix composition in the form of a powder, comprising:
a tissue matrix material obtained from mammalian urinary tract tissue, the tissue matrix material in the form of a sterile powder and including submucosa and lamina propria from the urinary tract tissue, wherein the tissue matrix material retains a proteoglycan, a growth factor, a glycoprotein, and a glycosaminoglycan.